Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Net Cash Flow (2016 - 2025)

Dare Bioscience (DARE) has disclosed Net Cash Flow for 11 consecutive years, with $18.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 446.44% year-over-year to $18.0 million, compared with a TTM value of $11.9 million through Sep 2025, up 531.49%, and an annual FY2024 reading of $5.3 million, up 122.06% over the prior year.
  • Net Cash Flow was $18.0 million for Q3 2025 at Dare Bioscience, up from -$5.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $36.5 million in Q3 2021 and bottomed at -$14.8 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $1.0 million, with a median of -$3.5 million recorded in 2023.
  • The sharpest move saw Net Cash Flow surged 87127.9% in 2021, then crashed 996.92% in 2024.
  • Year by year, Net Cash Flow stood at $6.1 million in 2021, then tumbled by 196.9% to -$5.9 million in 2022, then soared by 41.06% to -$3.5 million in 2023, then skyrocketed by 230.5% to $4.5 million in 2024, then skyrocketed by 297.43% to $18.0 million in 2025.
  • Business Quant data shows Net Cash Flow for DARE at $18.0 million in Q3 2025, -$5.3 million in Q2 2025, and -$5.4 million in Q1 2025.